Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

222 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide.
Harrison CN, Mead AJ, Panchal A, Fox S, Yap C, Gbandi E, Houlton A, Alimam S, Ewing J, Wood M, Chen F, Coppell J, Panoskaltsis N, Knapper S, Ali S, Hamblin A, Scherber R, Dueck AC, Cross NCP, Mesa R, McMullin MF. Harrison CN, et al. Blood. 2017 Oct 26;130(17):1889-1897. doi: 10.1182/blood-2017-05-785790. Epub 2017 Aug 9. Blood. 2017. PMID: 29074595 Free PMC article. Clinical Trial.
V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis.
Campbell PJ, Griesshammer M, Döhner K, Döhner H, Kusec R, Hasselbalch HC, Larsen TS, Pallisgaard N, Giraudier S, Le Bousse-Kerdilès MC, Desterke C, Guerton B, Dupriez B, Bordessoule D, Fenaux P, Kiladjian JJ, Viallard JF, Brière J, Harrison CN, Green AR, Reilly JT. Campbell PJ, et al. Among authors: harrison cn. Blood. 2006 Mar 1;107(5):2098-100. doi: 10.1182/blood-2005-08-3395. Epub 2005 Nov 17. Blood. 2006. PMID: 16293597 Free article.
Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation.
Campbell PJ, Baxter EJ, Beer PA, Scott LM, Bench AJ, Huntly BJ, Erber WN, Kusec R, Larsen TS, Giraudier S, Le Bousse-Kerdilès MC, Griesshammer M, Reilly JT, Cheung BY, Harrison CN, Green AR. Campbell PJ, et al. Among authors: harrison cn. Blood. 2006 Nov 15;108(10):3548-55. doi: 10.1182/blood-2005-12-013748. Epub 2006 Jul 27. Blood. 2006. PMID: 16873677 Free article.
JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis.
Scott LM, Tong W, Levine RL, Scott MA, Beer PA, Stratton MR, Futreal PA, Erber WN, McMullin MF, Harrison CN, Warren AJ, Gilliland DG, Lodish HF, Green AR. Scott LM, et al. Among authors: harrison cn. N Engl J Med. 2007 Feb 1;356(5):459-68. doi: 10.1056/NEJMoa065202. N Engl J Med. 2007. PMID: 17267906 Free PMC article.
MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort.
Beer PA, Campbell PJ, Scott LM, Bench AJ, Erber WN, Bareford D, Wilkins BS, Reilly JT, Hasselbalch HC, Bowman R, Wheatley K, Buck G, Harrison CN, Green AR. Beer PA, et al. Among authors: harrison cn. Blood. 2008 Jul 1;112(1):141-9. doi: 10.1182/blood-2008-01-131664. Epub 2008 May 1. Blood. 2008. PMID: 18451306 Free article.
Low-dose thalidomide in myelofibrosis.
Weinkove R, Reilly JT, McMullin MF, Curtin NJ, Radia D, Harrison CN. Weinkove R, et al. Among authors: harrison cn. Haematologica. 2008 Jul;93(7):1100-1. doi: 10.3324/haematol.12416. Epub 2008 May 27. Haematologica. 2008. PMID: 18508796 Free article. Clinical Trial. No abstract available.
Clonal diversity in the myeloproliferative neoplasms: independent origins of genetically distinct clones.
Beer PA, Jones AV, Bench AJ, Goday-Fernandez A, Boyd EM, Vaghela KJ, Erber WN, Odeh B, Wright C, McMullin MF, Cullis J, Huntly BJ, Harrison CN, Cross NC, Green AR. Beer PA, et al. Among authors: harrison cn. Br J Haematol. 2009 Mar;144(6):904-8. doi: 10.1111/j.1365-2141.2008.07560.x. Epub 2009 Jan 16. Br J Haematol. 2009. PMID: 19170680 Free article.
222 results